NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis.
The NF-E2 p45-related factor 2 (NRF2) and the aryl hydrocarbon receptor (AHR) are transcription factors controlling pathways modulating xenobiotic metabolism. AHR has recently been shown to affect Nrf2 expression. Conversely, this study demonstrates that NRF2 regulates expression of Ahr and subsequently modulates several downstream events of the AHR signaling cascade, including (i) transcriptional control of the xenobiotic metabolism genes Cyp1a1 and Cyp1b1 and (ii) inhibition of adipogenesis in mouse embryonic fibroblasts (MEFs). Constitutive expression of AHR was affected by Nrf2 genotype. Moreover, a pharmacological activator of NRF2 signaling, CDDO-IM {1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole}, induced Ahr, Cyp1a1, and Cyp1b1 transcription in Nrf2+/+ MEFs but not in Nrf2-/- MEFs. Reporter analysis and chromatin immunoprecipitation assay revealed that NRF2 directly binds to one antioxidant response element (ARE) found in the -230-bp region of the promoter of Ahr. Since AHR negatively controls adipocyte differentiation, we postulated that NRF2 would inhibit adipogenesis through the interaction with the AHR pathway. Nrf2-/- MEFs showed markedly accelerated adipogenesis upon stimulation, while Keap1-/- MEFs (which exhibit higher NRF2 signaling) differentiated slowly compared to their congenic wild-type MEFs. Ectopic expression of Ahr and dominant-positive Nrf2 in Nrf2-/- MEFs also substantially delayed differentiation. Thus, NRF2 directly modulates AHR signaling, highlighting bidirectional interactions of these pathways.
Shin
Soona
S
Department of Pharmacology and Molecular Sciences, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA.
Wakabayashi
Nobunao
N
Misra
Vikas
V
Biswal
Shyam
S
Lee
Gum Hwa
GH
Agoston
Elin S
ES
Yamamoto
Masayuki
M
Kensler
Thomas W
TW
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D017667:Adipocytes / Q000502:physiology; D050156:Adipogenesis / Q000502:physiology*; D000818:Animals; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology / Q000502:physiology; D005786:Gene Expression Regulation; D017930:Genes, Reporter; D000072019:Kelch-Like ECH-Associated Protein 1; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D018336:Receptors, Aryl Hydrocarbon / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D014158:Transcription, Genetic
D048868:Adaptor Proteins, Signal Transducing; D003598:Cytoskeletal Proteins; C117301:Keap1 protein, mouse; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; D018336:Receptors, Aryl Hydrocarbon
Drug Metab Dispos. 1995 Jun;23(6):642-50
7587946
Biochem Biophys Res Commun. 2004 May 28;318(2):571-8
15120638
Mol Cell Biol. 1996 Aug;16(8):4128-36
8754811
Cancer Res. 1997 Oct 15;57(20):4498-506
9377560
Physiol Rev. 1998 Jul;78(3):783-809
9674695
Mol Pharmacol. 1998 Aug;54(2):313-21
9687573
J Cell Sci. 1998 Nov;111 ( Pt 22):3311-22
9788873
Genes Dev. 1999 Jan 1;13(1):76-86
9887101
Arch Biochem Biophys. 2005 Jan 15;433(2):379-86
15581594
Biochem Pharmacol. 2005 Jan 15;69(2):199-207
15627472
Biochimie. 2005 Jan;87(1):51-6
15733737
J Biol Chem. 2005 May 27;280(21):20340-8
15790560
Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4
15936931
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9218-23
15972329
Arch Biochem Biophys. 2005 Jul 15;439(2):139-53
15967407
Toxicol Sci. 2005 Aug;86(2):342-53
15888666
Toxicol Lett. 2005 Aug 14;158(2):140-51
15890477
Oncogene. 2005 Nov 24;24(53):7869-81
16091746
Biochem Biophys Res Commun. 2006 Jan 6;339(1):79-88
16293230
Mol Cell Biol. 2006 Jan;26(1):221-9
16354693
Mol Pharmacol. 2006 Jan;69(1):140-53
16214954
Cell Metab. 2006 Mar;3(3):211-22
16517408
Trends Biochem Sci. 2006 May;31(5):284-91
16616498
Curr Drug Targets. 2006 May;7(5):589-95
16719769
Biochem Pharmacol. 2004 May 15;67(10):1897-905
15130766
Biochem Biophys Res Commun. 2004 Jun 18;319(1):235-9
15158467
Curr Opin Lipidol. 2004 Jun;15(3):303-7
15166786
Mol Cell Biol. 2004 Jun;24(12):5209-22
15169886
Proc Natl Acad Sci U S A. 1990 Aug;87(16):6258-62
2166952
Annu Rev Pharmacol Toxicol. 2007;47:89-116
16968214
Drug Metab Pharmacokinet. 2006 Dec;21(6):437-57
17220560
Mol Cancer Ther. 2007 Jan;6(1):154-62
17237276
Drug News Perspect. 2007 Mar;20(2):109-17
17440634
Biochem Pharmacol. 2007 Jun 15;73(12):1853-62
17266942
Nat Rev Genet. 2007 Jun;8(6):437-49
17510664
J Exp Biol. 2006 Jun;209(Pt 12):2337-43
16731810
Curr Opin Hematol. 2006 Jul;13(4):229-36
16755218
Biochem Pharmacol. 2006 Sep 28;72(7):795-805
16780804
Biochem Pharmacol. 2000 Jan 1;59(1):65-85
10605936
Genes Dev. 2000 Jun 1;14(11):1293-307
10837022
J Cell Sci. 2001 Aug;114(Pt 15):2809-17
11683414
Mol Cell Biol. 2002 May;22(9):2883-92
11940647
Trends Mol Med. 2002 Sep;8(9):442-7
12223316
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Biochem Biophys Res Commun. 2003 Mar 28;303(1):105-11
12646173
Biol Pharm Bull. 2003 Sep;26(9):1266-71
12951469
Biochem Pharmacol. 2003 Oct 1;66(7):1231-44
14505802
Nat Genet. 2003 Nov;35(3):238-45
14517554
Biochem J. 2004 Jan 1;377(Pt 1):205-13
14510636
Toxicol Sci. 2004 Mar;78(1):41-9
14691211
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6731-6
8692887